

RLL-266US

JC07 Rec'd PCT/PTO 02 MAY 2005

10/517101



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: KUMAR et al.

Serial No.: 10/517,101

Examiner: TBA

Filing Date: December 7, 2004

Group Art Unit: TBA

Title: MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS


CERTIFICATE OF MAILING

I certify that the following correspondence:

- Transmittal of Information Disclosure Statement
- Information Disclosure Citation
- Copies of cited references
- Postcard


is being deposited on April 27, 2005 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Box 313(b) Washington, D.C. 20231.

  
Kim Campbell

 <b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. <b>RLL-266US</b>	
In Re Application of <b>KUMAR et al.</b>						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/517,101	December 7, 2004	TBA	26815	TBA	TBA	
Title: <b>MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS</b>						
Address to: <b>Commissioner for Patents</b> <b>P.O. Box 1450</b> <b>Alexandria, VA 22313-1450</b>						
<b>37 CFR 1.97(b)</b>						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
<b>37 CFR 1.97(c)</b>						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);         </div>						
<b>OR</b>						
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).         </div>						

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. RLL-266US	
In Re Application: <b>KUMAR et al.</b>						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/517,101	December 7, 2004	TBA	26815	TBA	TBA	
Title: <b>MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS</b>						
<b>Payment of Fee</b> (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))						
<input type="checkbox"/> A check in the amount of _____ is attached. <input type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below. <input type="checkbox"/> Charge the amount of _____ <input type="checkbox"/> Credit any overpayment. <input type="checkbox"/> Charge any additional fee required. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.						
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>						
<b>Certificate of Transmission by Facsimile*</b>			<b>Certificate of Mailing by First Class Mail</b>			
I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____).  _____ (Date)  _____ Signature  _____ Typed or Printed Name of Person Signing Certificate			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____. April 27, 2005 (Date) _____ Signature of Person Mailing Correspondence Kim Campbell _____ Typed or Printed Name of Person Mailing Certificate			
*This certificate may only be used if paying by deposit account.						
_____ William D. Hare Signature			Dated: April 26, 2005			
William D. Hare, Esq. Reg. No. 44,739  Customer No. 26815						
CC:						

# INFORMATION DISCLOSURE CITATION



Docket No.: RLL-266US

Serial No.: 10/517,101

Applicants: K. AR *et al.*

Filed: 12/7/2004

Group:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,713,248	12/15/1987	Kjørnæs <i>et al.</i>	424	468	
	A2	5,783,215	7/21/1998	Arwidsson <i>et al.</i>	424	501	
	A3	6,274,171	8/14/2001	Sherman <i>et al.</i>	424	461	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	B1	WO 99/12524	3/18/1999	PCT	A61K	9/20		
	B2	WO 03/41692	5/22/2003	PCT	A61K	9/50		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Hunnius – Pharmazeutisches Wörterbuch. Walter deGruyter Verlag, Berlin, 7 <sup>th</sup> ed., 1993, Page 1497

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.